Neurogen Biomarking

Executive Summary

Neurogen Biomarking is a San Diego-based diagnostics company revolutionizing early Alzheimer's disease detection with an innovative at-home testing ecosystem. The company combines a blood-based biomarker test, digital cognitive assessments, and neurologist consultations to identify Alzheimer's risk decades before severe symptoms arise. Founded in 2018, Neurogen has achieved regulatory approval, positioning it as a potential leader in proactive memory health management. Its integrated approach addresses a critical gap in Alzheimer's care—early, accessible detection—offering a scalable solution in a market where delayed diagnosis is common. By enabling users to self-administer tests and receive expert follow-up, Neurogen aims to lower barriers to screening and facilitate earlier intervention, which could significantly impact patient outcomes and healthcare costs. The company operates in a rapidly growing market driven by aging populations, increasing Alzheimer's prevalence, and demand for non-invasive diagnostics. Neurogen's distinct advantage lies in its end-to-end platform, which not only detects biomarkers but also provides cognitive assessments and specialist guidance, creating a comprehensive care pathway. While competition from other blood-test developers and cognitive assessment tools exists, Neurogen's approved status and integrated model offer a strong value proposition. Looking ahead, the company is well-positioned to capture market share through strategic partnerships and reimbursement expansions. However, execution risks include adoption rates, clinical validation requirements, and competitive pressures. Overall, Neurogen Biomarking represents a promising investment opportunity in precision diagnostics for neurodegenerative diseases.

Upcoming Catalysts (preview)

• Q4 2026Expansion of Medicare coverage for at-home Alzheimer's testing60% success
• Q2 2026Publication of real-world validation study in primary care settings70% success
• Q3 2026Strategic partnership with a major health system for nationwide rollout50% success